Oncopeptides offers new FDA Approved Treatment Option for Some Patients with Triple-Class Refractory Multiple Myeloma

Oncopeptides will host a seminar to explore a new therapy for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

Join OncLive® and Oncopeptides, along with experts Joseph Mikhael, MD and Joshua Richter, MD for the seminar on Tuesday, April 13 or Wednesday, April 14.

See the brochure for more details:


Register at:  https://studio.mjhassoc.com/reach/oncopeptides-mm-broadcast

No comments have been posted yet.